June 15, 2024

Protein Therapeutics Market Size to Attain USD 696.89 Bn By 2033

The global protein therapeutics market size accounted for US$ 350.31 billion in 2023 and is projected to reach around USD 696.89 billion by 2033, growing at a CAGR of 7.12% from 2024 to 2033.

Protein Therapeutics Market Size 2024 to 2033

Key Points

  • North America dominated the market with a 45% Market share in 2023.
  • Asia Pacific is expected to witness the fastest growth rate in the market during the forecast period.
  • By product, the monoclonal antibodies segment dominated the market in 2023.
  • By product, the insulin segment is expected to grow substantially during the forecast period.
  • By application, the metabolic disorders segment dominated the market in 2023.
  • By application, the immunological disorders segment is expected to grow substantially during the forecast period.

Report Summary

The global protein therapeutics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the protein therapeutics market across the globe.

A comprehensive estimate on the protein therapeutics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of protein therapeutics during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3800

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized protein therapeutics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Polysilicon Market Size to Attain USD 37.84 Billion by 2033

Market Players

The report includes the profiles of key protein therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Recent Developments

  • In February 2024, BioNtech, a next-generation immunotherapy company, and Autolus, a clinical-stage biopharmaceutical company, announced the strategic collaboration for CAR-T Cell Therapy.
  • In February 2024, Lumosa Therapeutics, a Taiwan-based firm, introduced two Phase II clinical trials, LT3001, a candidate for treating acute ischemic stroke (AIS). The Phase IIb Bright (NCT05403866) trial and Phase II Lumosa 203 trial (NCT05198323) are double-blinded, placebo-controlled.
  • In January 2024, Ractigen Therapeutics, a leading clinical-stage pharmaceutical industry leader in charge of small activated RNA therapeutics, announced a strategic partnership with Utrecht University-affiliated University Medical Center. The collaboration strengthens the saRNA-based treatments for a spectrum of intractable neurodevelopmental disorders.
  • In January 2022, Thermo Fisher Scientific, Inc. paid US$ 1.85 billion in cash to acquire PeproTech. Privately held, PeproTech is a supplier of bioscience reagents, such as growth factors and cytokines, to the cell and gene therapy industry as well as other applications involving cell culture. PeproTech is headquartered in Cranbury, New Jersey.

Protein Therapeutics Market Companies

  • Bayer AG
  • Bristol-Myers Squibb
  • Daiichi Sankyo Company
  • Abbott
  • Sanofi
  • Thermo Fisher Scientific, Inc.
  • Genzyme Corporation (Sanofi)
  • AbbVie, Inc.
  • Sanofi
  • Leadiant Biosciences
  • Takeda Pharmaceutical Company Limited
  • Amicus Therapeutics

Segments Covered in the Report

By Product

  • Monoclonal Antibodies
  • Insulin
  • Fusion Protein
  • Erythropoietin
  • Interferon
  • Human Growth Hormone
  • Follicle Stimulating Hormone

By Applications

  • Metabolic Disorders
  • Immunologic Disorders
  • Hematological Disorders
  • Cancer
  • Hormonal Disorders
  • Genetic Disorders

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

 

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com